Literature DB >> 33662273

Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer.

Maciej Cieśla1, Phuong Cao Thi Ngoc1, Eugenia Cordero2, Álvaro Sejas Martinez1, Mikkel Morsing2, Sowndarya Muthukumar1, Giulia Beneventi1, Magdalena Madej1, Roberto Munita1, Terese Jönsson1, Kristina Lövgren3, Anna Ebbesson3, Björn Nodin3, Ingrid Hedenfalk3, Karin Jirström3, Johan Vallon-Christersson3, Gabriella Honeth3, Johan Staaf3, Danny Incarnato4, Kristian Pietras2, Ana Bosch5, Cristian Bellodi6.   

Abstract

Splicing is a central RNA-based process commonly altered in human cancers; however, how spliceosomal components are co-opted during tumorigenesis remains poorly defined. Here we unravel the core splice factor SF3A3 at the nexus of a translation-based program that rewires splicing during malignant transformation. Upon MYC hyperactivation, SF3A3 levels are modulated translationally through an RNA stem-loop in an eIF3D-dependent manner. This ensures accurate splicing of mRNAs enriched for mitochondrial regulators. Altered SF3A3 translation leads to metabolic reprogramming and stem-like properties that fuel MYC tumorigenic potential in vivo. Our analysis reveals that SF3A3 protein levels predict molecular and phenotypic features of aggressive human breast cancers. These findings unveil a post-transcriptional interplay between splicing and translation that governs critical facets of MYC-driven oncogenesis.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DRP1; MYC; SF3A3; alternative splicing; cancer plasticity; cancer stem cells; eIF3D; mitochondrial dynamics; translation control; triple-negative breast cancer

Year:  2021        PMID: 33662273     DOI: 10.1016/j.molcel.2021.01.034

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  7 in total

1.  Comprehensive analysis of spliceosome genes and their mutants across 27 cancer types in 9070 patients: clinically relevant outcomes in the context of 3P medicine.

Authors:  Zhen Ye; Aiying Bing; Shulian Zhao; Shuying Yi; Xianquan Zhan
Journal:  EPMA J       Date:  2022-05-10       Impact factor: 8.836

Review 2.  Protein synthesis control in cancer: selectivity and therapeutic targeting.

Authors:  Joanna R Kovalski; Duygu Kuzuoglu-Ozturk; Davide Ruggero
Journal:  EMBO J       Date:  2022-03-22       Impact factor: 14.012

3.  E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter.

Authors:  Kai-Long Liu; Yue-Wei Yin; Bao-Sai Lu; Ya-Lin Niu; Dan-Dan Wang; Bei Shi; Hong Zhang; Ping-Ying Guo; Zhan Yang; Wei Li
Journal:  Cancer Cell Int       Date:  2022-03-05       Impact factor: 5.722

4.  CircSCAP interacts with SF3A3 to inhibit the malignance of non-small cell lung cancer by activating p53 signaling.

Authors:  Dongni Chen; Hongli Zhou; Zhuochen Cai; Kaican Cai; Ji Liu; Weidong Wang; Huikai Miao; Hongmu Li; Rongzhen Li; Xiaodong Li; Youfang Chen; Hui-Yun Wang; Zhesheng Wen
Journal:  J Exp Clin Cancer Res       Date:  2022-04-01

5.  TDP43 promotes stemness of breast cancer stem cells through CD44 variant splicing isoforms.

Authors:  Lu Guo; Hao Ke; Honglei Zhang; Li Zou; Qin Yang; Xuemei Lu; Limin Zhao; Baowei Jiao
Journal:  Cell Death Dis       Date:  2022-05-03       Impact factor: 9.685

6.  Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach.

Authors:  Junjie Jiang; Yongfeng Ding; Jun Lu; Yanyan Chen; Yiran Chen; Wenyi Zhao; Wenfan Chen; Mei Kong; Chengzhi Li; Xiaodong Teng; Quan Zhou; Nong Xu; Donghui Zhou; Zhan Zhou; Haiyong Wang; Lisong Teng
Journal:  Int J Biol Sci       Date:  2022-08-29       Impact factor: 10.750

7.  The small Cajal body-specific RNA 15 (SCARNA15) directs p53 and redox homeostasis via selective splicing in cancer cells.

Authors:  Giulia Beneventi; Roberto Munita; Phuong Cao Thi Ngoc; Magdalena Madej; Maciej Cieśla; Sowndarya Muthukumar; Nicolai Krogh; Henrik Nielsen; Vinay Swaminathan; Cristian Bellodi
Journal:  NAR Cancer       Date:  2021-07-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.